Introduction
The incidence of diabetes mellitus (DM) is rapidly growing, paralleling social and cultural changes of Western society. In particular, the ageing process, urbanization, sedentariness, and changes in dietary habits seem to play a significant role in this epidemiological trend. 1 About 8 .5% of all European adults are affected by DM. 2 In USA, the prevalence of DM in people >75 years is 14.9% and, with undiagnosed forms, could be as high as 28. 3% . 3 Approximately 20% of diabetic patients have atrial fibrillation (AF). 4 The Framingham Heart Study showed that the presence of DM favoured the development of incident AF, both in men and
Methods
The EORP-AF Registry
The baseline features and the main results of the EORP-AF Registry have been previously published. 10, 11 In brief, the EORP-AF Registry, established by the European Society of Cardiology (ESC), originates from the need to know how ESC participating countries manage AF patients, the degree of concordance of medical treatment with current guidelines, and what is the current long-term prognosis of the arrhythmia. 10, 11 Between February 2012 and March 2013, consecutive patients were enrolled in 70 centres in nine European Countries (i.e. Belgium, Denmark, Greece, Italy, Norway, Poland, Portugal, Romania, and The Netherlands). The Registry population comprised in-and outpatients with an AF documented by 12-lead electrocardiogram (ECG), 24-h Holter ECG, or other ECG recordings. The qualifying episode should have occurred in the last 12 months, independently of its presence at the time of enrollment. A primary or secondary diagnosis of AF was allowed. Each centre had to recruit at least 20 patients, with a total target Registry population of 3000 subjects. Follow-up visits were scheduled at 12, 24, and 36 months. 10, 11 For the purpose of this study, we will present data at the 12-month evaluation only. Our landmark analysis, such as in the first follow-up EORP-AF Registry report, 11 was always centred on this time window in order to avoid attrition and to maintain an adequate sample size. At baseline and at the follow-up, clinical data, HRQL evaluation, and drug therapy were collected in an electronic web-based chart. Hospital charts and other medical reports constituted the preferred source of information for the follow-up evaluation. Bleeding events were classified according to the criteria of the International Society on Thrombosis and Haemostasis. 12 Laboratory and instrumental data were obtained at baseline only. Health-related quality of life was assessed with a selfadministered questionnaire (atrial fibrillation quality of life questionnaire (AF-QoL)) consisting of 18 items exploring psychological (7 items), physical (8 items), and sexual (3 items) domains. All questions refer to feelings perceived in the preceding month and can be answered on a five-point Likert scale (from 1 to 5), with lower scores indicating a greater negative impact of the arrhythmia on HRQL. 13 The Ethical Committee of all participating centres approved the study protocol.
Statistical analysis
For the aim of this study, the EORP-AF Registry population was stratified into two groups according to the presence of DM.
Continuous variables are reported as mean ± standard deviation or as median and interquartile range. Between-group comparisons were made using a non-parametric test (the Kruskal-Wallis test). Categorical variables are reported as percentages (without missing values if applicable).
Between-group comparisons were made using a v 2 test or a Fisher's exact test (if any expected cell count was less than five). For qualitative variables with more than two possibilities, the Monte Carlo estimates of the exact P-values were used. Plots of the Kaplan-Meier curves for death according to DM status (diabetic patients vs. non-diabetic patients) were performed. The survival distributions were compared using the log-rank test. The consistency of the influence of DM on mortality across specific subgroups of patients was tested with the Cochran-Mantel-Haenszel Statistics.
A stepwise multiple Cox regression analysis was used to determine the predictors of all causes of death including all the candidate variables (variables with P < 0.10 in univariate analysis). A significance level of 0.05 was required to allow variable entrance (SLENTRY = 0.05) and stay into the model (SLSTAY = 0.05). No interaction was tested. A Hosmer and Lemeshow Goodness-of-Fit test was used to verify that the model was optimal.
A two-sided P-value of <0.05 was considered as statistically significant. All analyses were performed using SAS statistical software version 9.3 (SAS Institute, Inc., Cary, NC, USA).
Results
The EORP-AF Investigators enrolled 3 101 patients (mean age 69 ± 11 years, men 59.7%). Mean CHA 2 DS 2 -VASc and HAS-BLED scores were, respectively, 3.2 ± 1.8 and 1.4 ± 1.1. Atrial fibrillation was the main diagnosis in 60.2% of cases, and the prevalence of DM was 20.6% (N = 638/3101). Diabetic patients were older and as expected, had a higher prevalence of comorbidities ( Table 1) . Accordingly, mean CHA 2 DS 2 -VASc score was higher, with almost all diabetic subjects being in the high-risk group. When DM was present, AF was responsible for hospitalization or evaluation in the ambulatory or outpatient clinic in a lower proportion of cases ( Table 1) .
Patients with DM more often presented with permanent AF and had a lower prevalence of paroxysmal AF. Of presenting symptoms, dyspnoea, and chest pain were more commonly seen in diabetic subjects.
Health-related quality of life
Data on HRQL are available for 1877 patients (60.5% of the whole population). The presence of DM was associated to a worse HRQL, with lower AF-QoL scores in total, psychological, physical, and sexual activity domains ( Table 1) . The higher CHA 2 DS 2 -VASc score of diabetic individuals explained these differences. Indeed, at bivariate analysis, each point of increase of the CHA 2 DS 2 -VASc was associated with a mean reduction of the total AF-QoL score of 2.5 ± 0.3 points (P < 0.0001); in this model, DM lost its statistical significance (P = 0.998).
Rhythm-and rate-control strategies
While pharmacological cardioversion did not differ by group, external electrical cardioversion (ECV) and ablation procedures were significantly more common in non-DM subjects ( Table 2) .
In a symptomatic population, a rhythm-control strategy was the preferred option independent of the presence of DM (diabetic patients 68.1% vs. non-diabetic patients 68.2%, P = 0.3556). If symptoms were absent, sinus rhythm restoration was more frequently pursued in subjects without DM (29.5 vs. 42 .9%, P = 0.0002).
.
Accordingly, the use of Class IC antiarrhythmic drugs was more common in non-DM patients, while we did not find any difference in the use of Class III agents, beta-blockers, and non-dihydropyridine calcium antagonists ( Table 3) .
Given the higher prevalence of chronic heart failure (CHF), an implantable cardioverter-defibrillator was more frequently used in DM patients ( Table 2) 27 .3% of cases, respectively. Drugs acting on the renin angiotensin system, anti-aldosterone agents, digitalis, diuretics, dihydropyridine calcium antagonists, and statins were commonly prescribed if DM was present (Table 3) . Overall, 95.3% of our subjects were prescribed an antithrombotic drug; the proportion was significantly higher in the case of DM because of a larger use of both oral anticoagulants and antiplatelet agents ( Table 3) . At discharge from hospital or at the end of the enrollment visit, the combined use of an anticoagulant with an antiplatelet agent was observed in 29.4% and 17.6% of diabetic and nondiabetic subjects, respectively (P < 0.0001). At the 1-year follow-up, the proportion of patients taking an oral anticoagulant was only slightly reduced from baseline (DM 82.9 vs. non-DM 75.3%, P = 0.0004). Therapy with antiplatelet agents alone (DM 34.7 vs. non-DM 26.5%, P = 0.0003) or in combination with an anticoagulant drug (DM 23.7 vs. non-DM 13.7%, P < 0.0001) followed the same trend.
In-hospital and acute adverse events
Patients were enrolled during their in-hospital stay in 64.0% of cases, with the remaining enrolled from outpatients and ambulatory settings. Overall mortality was 0.5% (N = 10/1984), higher, yet not statistically significant, in patients with DM (P = 0.0507) (Figure 1) .
Major complications during hospitalization or in the 15 days following the enrollment occurred in 11.5% (N = 177) of non-diabetic and in 12.8% (N = 57) of diabetic patients (P = 0.4391), respectively. No differences between the DM and non-DM groups were observed in the incidence of cardio-embolic events, intra-cerebral haemorrhage or major bleeding, CHF, AF recurrence, bradyarrhythmias, and ventricular tachyarrhythmias (Figure 1 ).
Mortality and adverse events at follow-up
Follow-up data at 12 months were available for 84.7% of the whole population (N = 2627/3101). The composite of all thromboembolic events was higher in DM patients (5.6 vs. 3 .5%, P = 0.0439). The incidence of stroke/transient ischaemic attack (TIA) (on the whole, 1.0%), and of peripheral or pulmonary embolism (on the whole, 0.1%) was low and not different between groups (P = 0.5875 and P = 1.0000, respectively). New coronary events were significantly higher if DM was present, whilst the incidence of major bleeding was low (on the whole, 1.1%) and not different in the two groups of subjects (P = 0.2999) (Figure 2 At the 12-month evaluation, 6 .3% (N = 166/2627) of the enrolled population was dead. Overall mortality was significantly higher in DM patients and, on the Kaplan-Meier analysis, survival curves diverged immediately after the enrollment (Figure 3) . Amongst DM patients, mortality for both cardiovascular and non-cardiovascular causes was also higher (Figure 2) . The association between DM and mortality persisted also in the subgroup analysis. In particular, no differences in behaviour were observed among age (<75 vs. > _75 years, P < 0.001), gender (men vs. women, P < 0.001), and CHA 2 DS 2 -VASC (low vs. moderate vs. high risk score, P < 0.001) strata.
Univariate and multivariate analysis of mortality
Univariate predictors of all-cause mortality were age and several important comorbidities, such as coronary artery disease (CAD), CHF, chronic obstructive pulmonary disease, chronic renal failure (CRF), malignant neoplasms, and TIA. Better HRQL was associated with reduced mortality (P = 0.0068). New minor bleeding and thromboembolic events during the follow-up identified the high-risk group. Improved survival was associated with AF as the main diagnosis and the presence of AF-related symptoms at the baseline evaluation. Among therapies, the use of oral anticoagulants and statins was higher in those who survived ( Table 4) .
Cox multivariate analysis (P for the whole model <0.0001) confirmed that DM, even after adjustment, was a significant independent predictor of all-cause mortality. Diabetic subjects had a risk of events nearly twofold higher than the non-DM AF population (hazard ratio (HR) 1.86 , 95% confidence interval (CI) 1.31-2.62; P = 0.0004). The other clinical variables, independently associated with prognosis, were age, the presence of CHF, CRF, a previous TIA, and minor 
Discussion
In this ancillary analysis from the EORP-AF Pilot Registry, DM was present in 20.6% of the cohort, and was associated with older age, more comorbidities and higher cardio-embolic risk. AF patients with DM, because of their higher CHA 2 DS 2 -VASc score, had a worse HRQL. After 12 months, even after adjustment, all-cause, cardiovascular and non-cardiovascular mortality were significantly higher when DM was present. The high proportion of diabetic individuals in the EORP-AF Registry is consistent with the contemporary age-dependent increase in the prevalence of both DM 3 and AF. Indeed, the arrhythmia can be found in 14.7% and 23.4% of subjects aged 75-84 and > _85 years, respectively. 14 Furthermore, a large meta-analysis reported that DM associates with an about 40% higher risk of incident AF. 15 Lack of glycaemic control, increased atrial fibrosis, augmented sympathetic activity and the associated changes in electrical properties of atrial tissue all contribute to the multifactorial link between the two conditions. 16 Diabetes mellitus is a well-established risk factor for thromboembolic events. 8, 9 Recently, the European Prevention of thromboembolic events-European Registry in Atrial Fibrillation (PREFER in AF) showed that insulin-dependent diabetics had a significantly higher risk of stroke or systemic embolism at 1-year follow-up compared to non-insulin dependent type 2 diabetics or non-diabetics. 17 Furthermore, analyses of the nationwide Danish registries showed that duration of DM history could be a significant predictor of stroke. 18 In the EORP-AF Registry, antithrombotic therapy was more often prescribed in diabetic patients. Oral anticoagulants, even in association with antiplatelet agents, were more frequently used than in non-DM, consistent with prior reports, 19 proving that guideline recommendations are followed. Interestingly, one study exploring the quality of anticoagulation in a wide cohort of older patients, found that the presence of DM contributed to a significant reduction of time in therapeutic range amongst warfarin users. 20 In the EORP-AF Registry, the higher prevalence of CAD in diabetic patients explained a more frequent prescription of coronary angiography. Transoesophageal echocardiography was less often employed in subjects with DM, probably because of the lower use of ECV and AF ablation. The older age of the diabetic population could justify these findings. In a previous analysis of the EORP-AF Registry, we showed that both ECV and AF ablation were utilized more often in subjects <75 years than in those > _75 years. 21 Indeed, AF in elderly individuals may be considered a marker of frailty. 22 In this case, the rate-control strategy would be the preferred therapeutic option. Our study showed that diabetic patients, when compared with nondiabetics, were characterized by a worse HRQL. The total, and each single-domain score of the AF-QoL questionnaire, were significantly lower in DM subjects, and, at the follow-up, all-cause mortality was higher in those with a poor HRQL. The higher CHA 2 DS 2 -VASc score of the diabetic population largely explains these results. Indeed, in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), women had both a higher CHA 2 DS 2 -VASc score and a worse HRQL than men, and showed a progressively poorer psychological status with the increase of thromboembolic risk. 23 One of the most important findings of this study is the strong association between DM and prognosis at the follow-up, with an all-cause mortality risk nearly two-fold higher in DM than in non-DM subjects. A similar, albeit quantitatively lower excess of all-cause mortality risk (HR 1.23, 95% CI 1.03-1.46), was observed in the Loire Valley Atrial Fibrillation Project, where no differences in the incidence of thromboembolic events and bleeding were evident according to the presence of DM. 24 The link between AF and prognosis, observed in our diabetic patients, is strengthened by the relation of DM with some of the comorbidities associated with 1-year mortality. Indeed, the prevalence of systolic CHF, CRF and a previous TIA was higher in diabetic subjects. It was already found that in patients with CHF, the presence of DM increased the risk of new hospitalizations and cardiovascular mortality during a follow-up of 9.9 months. 25 Furthermore, it was shown that CRF of any degree was associated with higher all-cause mortality in AF patients. 26 Our results, based on a European experience, are enforced by those recently obtained by the ORBIT-AF Registry, in a wide, prospectively enrolled, USA population (N = 9479) stratified by metabolic status. Also in this case, diabetic patients presented a higher burden of comorbid conditions but, in contrast with what we found, they were younger than controls. As in the EORP-AF Pilot Registry, diabetic population was more likely to receive anticoagulant therapy and characterized by a higher mortality risk. 27 Interestingly, also ORBIT-AF diabetic patients, when compared to those without DM, showed a worse HRQL, 27 a finding that we proved closely correlated to clinical complexity, as expressed by the CHA 2 DS 2 -VASc score.
Limitations
This study is limited by its observational design and we cannot exclude the existence of differences in the evaluation and This prevented us from evaluating the independent effect of the variable on mortality in a multivariate model. Despite these limitations, the EORP-AF Registry allowed to better define clinical characteristics, management and the poor prognosis amongst AF patients presenting with DM.
Conclusions
Diabetic patients represent a large part of AF population. DM is associated with a higher prevalence of comorbidities and a worse impact on quality of life. After one year, despite a greater prescription of antithrombotic therapy, the diabetic population had a significantly higher all-cause, cardiovascular, and non-cardiovascular mortality.
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